

*Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**偉俊生物科技有限公司**

**Wai Chun Bio-Technology Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 660)**

**UNAUDITED ANNUAL RESULTS ANNOUNCEMENT  
FOR THE EIGHTEEN MONTHS ENDED 30 JUNE 2022**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Reference is made to the announcement of the Company dated 22 September 2022 in relation to, among others, the delay in publication of the audited annual results of the Group for the eighteen months ended 30 June 2022. In order to keep the shareholders of the Company (the “**Shareholders**”) and the public informed of the Group’s financial performance and position, the Board wishes to set forth below the preliminary unaudited consolidated financial information extracted from the draft management accounts of the Group for the eighteen months ended 30 June 2022. The Directors confirm that the following preliminary unaudited consolidated financial information is prepared on the same basis as used in the audited financial statements of the Group for the year ended and as of 31 December 2020.

The preliminary unaudited consolidated financial statements cover an eighteen months period ended 30 June 2022 and the comparative financial statements cover a twelve months year ended 31 December 2020. The comparative amounts are therefore not entirely comparable.

## UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the eighteen months ended 30 June 2022

|   | <b>1 January<br/>2021 to<br/>30 June<br/>2022<br/>HK\$'000<br/>(Unaudited)</b> | Year ended<br>31 December<br>2020<br>HK\$'000<br>(Audited) |
|---|--|--|
| <b>Revenue</b>  | <b>1,007,186</b>   | 567,553  |
| Cost of sales   | <u>(920,707)</u>   | <u>(518,623)</u>   |
| <b>Gross profit</b>                                       | <b>86,479</b>  | 48,930   |
| Other revenue and other gains and losses, net             | <b>(5,035)</b>   | (122)  |
| Selling expenses  | <b>(22,679)</b>  | (12,179)   |
| Administrative expenses                                   | <b>(39,274)</b>  | (25,519)   |
| Impairment losses on receivables, net of reversal         | –  | (1,584)  |
| Finance costs   | <u>(20,978)</u>  | <u>(7,915)</u>   |
| <b>(Loss) profit before tax</b>                           | <b>(1,487)</b>   | 1,611  |
| Income tax expense  | <u>(3,795)</u>   | <u>(616)</u>   |
| <b>(Loss) profit for the period/year</b>                  | <b>(5,282)</b>   | 995  |
| <b>(Loss) profit for the period/year attributable to:</b> |  |  |
| – Owners of the Company                                   | <b>(23,531)</b>  | (8,149)  |
| – Non-controlling interests                               | <b>18,249</b>  | 9,144  |
|   | <u><b>(5,282)</b></u>  | <u>955</u>   |
|   | <i>HK cents</i>  | <i>HK cents</i>  |
| <b>Loss per share</b>                                     |  |  |
| – Basic and diluted                                       | <u><b>(1.40)</b></u>   | <u>(0.49)</u>  |

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

*For the eighteen months ended 30 June 2022*

|  | <b>1 January<br/>2021 to<br/>30 June<br/>2022<br/>HK\$'000<br/>(Unaudited)</b> | Year ended<br>31 December<br>2020<br>HK\$'000<br>(Audited) |
|--|--|--|
| <b>(Loss) profit for the period/year</b>   | <u>(5,282)</u>   | <u>995</u>   |
| <b>Other comprehensive (expense) income:</b>                                     |  |  |
| <i>Item that may be reclassified to profit or loss:</i>                          |  |  |
| Exchange differences on translating foreign operations                           | <u>(1,752)</u>   | <u>3,207</u>   |
| <b>Other comprehensive (expense) income, net of tax</b>                          | <u>(1,752)</u>   | <u>3,207</u>   |
| <b>Total comprehensive (expense) income for the period/year</b>                  | <u><b>(7,034)</b></u>  | <u><b>4,202</b></u>  |
| <b>Total comprehensive (expense) income for the period/year attributable to:</b> |  |  |
| – Owners of the Company  | <u>(24,425)</u>  | <u>(6,513)</u>   |
| – Non-controlling interests  | <u>17,391</u>  | <u>10,715</u>  |
|  | <u><b>(7,034)</b></u>  | <u><b>4,202</b></u>  |

## UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

|  | <b>30 June</b><br><b>2022</b><br><i>HK\$'000</i><br><b>(Unaudited)</b> | 31 December<br>2020<br><i>HK\$'000</i><br><b>(Audited)</b> |
|--|--|--|
| <b>Non-current assets</b>                    |  |  |
| Property, plant and equipment                | <b>67,110</b>  | 61,093   |
| Right-of-use assets                          | <b>30,206</b>  | 36,981   |
|  | <b>97,316</b>  | 98,074   |
| <b>Current assets</b>                        |  |  |
| Inventories                                  | <b>69,748</b>  | 52,291   |
| Trade and bills receivables                  | <b>38,386</b>  | 13,769   |
| Deposits, prepayments and other receivables  | <b>36,277</b>  | 18,728   |
| Tax refundable                               | –  | 13   |
| Bank balances and cash                       | <b>7,520</b>   | 5,446  |
|  | <b>151,931</b>   | 90,247   |
| <b>Current liabilities</b>                   |  |  |
| Trade payables                               | <b>88,668</b>  | 43,192   |
| Accruals and other payables                  | <b>11,879</b>  | 25,058   |
| Contract liabilities                         | <b>1,242</b>   | 3,260  |
| Borrowings                                   | <b>71,809</b>  | 73,762   |
| Tax payable                                  | <b>4,648</b>   | –  |
| Lease liabilities                            | <b>1,284</b>   | 3,589  |
| Loans from the ultimate holding company      | <b>824</b>   | 1,128  |
|  | <b>180,354</b>   | 149,989  |
| <b>Net current liabilities</b>               | <b>(28,423)</b>  | (59,742)   |
| <b>Total assets less current liabilities</b> | <b>68,893</b>  | 38,332   |

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
(CONTINUED)**

*As at 30 June 2022*

|  | <b>30 June<br/>2022</b> | 31 December<br>2020    |
|--|-------------------------|------------------------|
|  | <i>HK\$'000</i>         | <i>HK\$'000</i>        |
|  | <b>(Unaudited)</b>      | <b>(Audited)</b>       |
| <b>Non-current liabilities</b>                           |                         |                        |
| Lease liabilities  | –                       | 3,161                  |
| Convertible bonds  | <u>65,650</u>           | <u>48,140</u>          |
|  | <u>65,650</u>           | <u>51,301</u>          |
| <b>Net assets (liabilities)</b>                          | <u><u>3,243</u></u>     | <u><u>(12,969)</u></u> |
| <b>Capital and reserves</b>                              |                         |                        |
| Share capital – ordinary shares                          | 42,019                  | 41,477                 |
| Share capital – convertible preference shares            | –                       | 542                    |
| Reserves   | <u>(80,686)</u>         | <u>(79,507)</u>        |
| Capital deficiency attributable to owners of the Company | (38,667)                | (37,488)               |
| Non-controlling interests                                | <u>41,910</u>           | <u>24,519</u>          |
| <b>Total equity (deficit)</b>                            | <u><u>3,243</u></u>     | <u><u>(12,969)</u></u> |

Shareholders and potential investors of the Company are reminded that the information contained in this announcement is only based on the preliminary assessment by the Board on the unaudited management accounts of the Group for the eighteen months ended 30 June 2022, and the information contained in this announcement has not been fully reviewed or audited by the auditor (“**Auditor**”) of the Company. The relevant financial information is pending for further review by the Company, its Auditor and the Audit Committee and will be subject to changes, reclassification and adjustments resulting from, among others, further review by the Company and the Auditor. The Board cannot guarantee the preliminary unaudited consolidated financial information has truly reflected the financial performance and condition of the Group if the potential adjustments have not been taken into account.

The preliminary figures disclosed above are subject to change and may differ from those appear in audited consolidated financial statements of the Group as the audit has not yet completed. As such they are strictly for information purpose only and not for any other purpose. Shareholders and potential investors of the Company are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the shares of the Company. Any Shareholder or potential investor of the Company who is in doubt is advised to seek advice from your own professional advisor.

Shareholders and potential investors of the Company are also cautioned not to unduly rely on the preliminary unaudited consolidated financial information disclosed above, and should exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Wai Chun Bio-Technology Limited**  
**Chan Cheuk Ho**  
*Executive Director*

Hong Kong, 30 September 2022

As at the date of this announcement, the Board comprises:

*Executive Director:*

CHAN Cheuk Ho

*Independent Non-executive Directors:*

WAN Bo

HAU Pak Man